Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    CSOM230C2303
Show Display Options
Rank Status Study
1 Completed
Has Results
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Condition: Symptomatic Refractory Resistant Carcinoid Disease
Interventions: Drug: Pasireotide;   Drug: Octreotide

Indicates status has not been verified in more than two years